March 4, 2020 / 8:11 AM / a month ago

BRIEF-Takeda Initiates Development Of A Plasma-Derived Therapy For Covid-19

March 4 (Reuters) - Takeda Pharmaceutical Co Ltd:

* TAKEDA INITIATES DEVELOPMENT OF A PLASMA-DERIVED THERAPY FOR COVID-19

* TAKEDA PHARMACEUTICAL CO LTD - TAKEDA INITIATES DEVELOPMENT OF A PLASMA-DERIVED THERAPY FOR COVID-19

* TAKEDA PHARMACEUTICAL CO LTD - EXPLORING POTENTIAL TO REPURPOSE MARKETED PRODUCTS AND MOLECULES TO POTENTIALLY TREAT COVID-19

* TAKEDA PHARMACEUTICAL - ALSO STUDYING WHETHER CO’S CURRENTLY MARKETED AND PIPELINE PRODUCTS MAY BE EFFECTIVE TREATMENTS FOR INFECTED PATIENTS

* TAKEDA PHARMACEUTICAL -INITIATING DEVELOPMENT OF AN ANTI-SARS-COV-2 POLYCLONAL HYPERIMMUNE GLOBULIN TO TREAT HIGH-RISK INDIVIDUALS WITH COVID-19

* TAKEDA PHARMACEUTICAL - TAKEDA WILL INITIALLY PRODUCE THERAPY IN A SEGREGATED AREA WITHIN ITS MANUFACTURING FACILITY IN GEORGIA Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below